|
  
|
|
 |  |  |  |  |  |  |  |
|
Nephrology & Urology
|
|
|
ATLANTA – Men in their 40s with a low prostate specific antigen can probably safely delay additional testing for 10-15 years. Young men with a higher baseline level, however, are twice as likely to develop prostate cancer over the same time period and should probably have their PSA tested at... »
U.S. Task Force Confirms Stance Against Universal PSA Screening
"Do not use prostate-specific antigen (PSA)–based screening for prostate cancer." With these words, the U.S. Preventive Services Task Force (USPSTF) finalized its stance against using this blood test to screen men universally in the United States for prostate cancer. This firm... »
NICE Reverses Course on Abiraterone
After initially turning it down – and being pressured to reevaluate by the U.K. Department of Health – the clinical effectiveness agency for England and Wales has decided to recommend abiraterone, in combination with glucocorticoids, as a second-line treatment for metastatic prostate cancer. The... »
SAN DIEGO – Terlipressin, widely used in Europe for hepatorenal syndrome but not yet approved in the United States, would be a useful option for this difficult-to-treat condition, said transplant hepatologist Dr. James... »
Renal Denervation Outcomes for Resistant Hypertension Persist at 3 Years
CHICAGO – Selective renal denervation for the treatment of resistant hypertension continues to rack up impressively large and durable blood pressure reductions and a solid safety profile 3 years post-procedure, according to... »
Urinary Dysfunction Stands Out on Retigabine's Safety Profile
BALTIMORE – The safety profile for retigabine is generally consistent with that of other antiepileptic drugs, but data from studies in its evaluation process show that it also carries a novel, small increased risk of urinary... »
ATLANTA – Men in their 40s with a low prostate specific antigen can probably safely delay additional testing for 10-15 years. Young men with a higher baseline level, however, are twice as likely to develop prostate cancer... »
U.S. Task Force Confirms Stance Against Universal PSA Screening
"Do not use prostate-specific antigen (PSA)–based screening for prostate cancer." With these words, the U.S. Preventive Services Task Force (USPSTF) finalized its stance against using this blood test to screen... »
NICE Reverses Course on Abiraterone
After initially turning it down – and being pressured to reevaluate by the U.K. Department of Health – the clinical effectiveness agency for England and Wales has decided to recommend abiraterone, in combination with... »
CHICAGO – Selective renal denervation for the treatment of resistant hypertension continues to rack up impressively large and durable blood pressure reductions and a solid safety profile 3 years post-procedure, according to... »
Men's Health RSS
Interested in being notified of new Men's Health news?
Click here to view our Men's Health RSS Feed.
| May 18 - 23 San Francisco, CA | American Thoracic Society (ATS): International Conference |
| May 19 - 24 Atlanta, GA | American Urological Association (AUA): Annual Meeting |
| May 19 - 23 Stockholm, | European Calcified Tissue Society (ECTS): Annual Congress |
| May 20 - 23 Brisbane, | Australasian College of Dermatologists: Annual Scientific Meeting |
| May 20 - 23 San Antonio, TX | American Pediatric Surgical Association (APSA): Annual Meeting |
| May 20 - 23 Washington, DC | American College of Emergency Physicians (ACEP): Leadership & Advocacy Conference |
| May 21 - 23 Nice, | 12th International Review of Bipolar Disorders (IRBD 12) |
| May 21 - 25 Sarasota, FL | American Medical Seminars: Cardiology Update in Primary Care |
| May 22 - 25 Lisbon, | 21st European Stroke Conference |
| May 23 - 27 Philadelphia, PA | American Association of Clinical Endocrinologists (AACE): Annual Meeting and Clinical Congress |